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Spasticite´ (I) / Revue d’E´pide´miologie et dedrive) at least in part. We define this stretch-sensitive, misdirected descending
command as spastic cocontraction. While spastic cocontraction is really the
main antagonistic mechanism impeding movement, in particular leg
movements during gait, muscle overactivity is often assumed to be represented
by mere measurements of resistance to passive movement. A five-step clinical
assessment, including a quantitative assessment of active range of motion, may
better serve the clinician to reflect the amount of cocontraction.
Another critical phenomenon is stretch-sensitive paresis, which is the aggravation
of paresis of agonist command by the stretched position of the antagonist. The
physiological underpinnings of spastic cocontraction and stretch-sensitive paresis
probably involve neuronal rarefaction in agonist command, hypo-excitabilty of
the remaining upper motor neurons, hyperexcitability of the lower motor neurons
subserving the more shortened muscles and reduction or reversal into facilitation
of Ia and groups II reciprocal inhibition.
Considering its determinants (agonist effort and muscle position), treatment of
spastic cocontraction and stretch-sensitive paresis – and management of
deforming spastic paresis in general – should logically involve a combination of:
– prolonged stretching postures for the more overactive and shortened
antagonists, potentially in association with focal weakening agents such as
botulinum toxin;
– intensive motor training (e.g. non assisted maximal amplitude rapid
alternating movements and task-related exercises) of the less overactive
muscles.
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Botulinum toxin is now the reference treatment in focal spasticity, however, in
the context of multiple sclerosis few studies have been conducted. The objective
of this work is to try to clarify the use of botulinum toxin in multiple sclerosis,
particularly in terms of indications.
Method.– We analyzed retrospectively all cases of patients with multiple
sclerosis who received botulinum toxin injection on the pole Saint-Hélier
between 2007 and 2010.
Results.– During these 4 years, 673 patients including 126 people with MS have
benefited from treatment with botulinum toxin. The population consists of 85
women and 41 men, mean age 49.4  11 years with an average EDSS score of
5.8  1.7 (2.5 to 9.5).
The most common indications are abnormal gait and difficulties in nursing.
The lower limbs are usually involved, only 11 patients have benefited injection
in the upper limbs. A specific indication was the vesico-sphincter dyssynergia
with nine people.
From the given files, different clinical situations can be described. The most
common indication is to improve walking, in this situation the triceps surae is
most often injected, in patients with a mean age 48.5  /11 years with an
average EDSS of 5  1.
For higher EDSS, the objective is to improve nursing care, positioning, in this
case, the most frequently injected muscles are adductors and hamstrings, our
population in this context has a mean EDSS of 7.7  1, with an average age of
52.4  11 years.
Patient satisfaction is generally high.
Discussion and conclusion.– The objective of this work was to have an overview
of the use of botulinum toxin in spasticity management in multiple sclerosis.
Two main indications have emerged: the gait disorders associated with
spasticity of the triceps surae and the difficulties of nursing, related to the
spasticity of the adductors.
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Introduction.– Spasticity is a frequent and handicapping symptom in patients
with LAS [1]. Before the use of botulinum toxin, the only treatment associated
physiotherapy and oral medication.
Methods.– Forty-five patients suffering from LAS with either paraparesia
(n = 10) or tetraparesia (n = 25) were referred to the specialized consultation in
Physical Rehabilitation Medicine department in order to treat their spasticity.
Some patients walked independently (n = 4), some required human or technical
help for deambulation (n = 38), some were unable to walk (n = 3). Their
medical charts were retrospectively analyzed, to determine the efficacy,
tolerance and side-effects of botulinum toxin therapy.
Results.– Thirty-nine patients received botulinum toxin injections in their
inferior members, in order to ameliorate ambulation (n = 36), sitting or nursing
(n = 3). In 16 patients, a motor bloc of rectus femoris muscle was made. Five
patients out of them were considered as ineligible for botulinum toxin therapy.
Twenty-one patients were satisfied with the treatment that was continued.
Eighteen patients stopped botulinum toxin therapy after the first injection either
because of lack of improvement either by diseased progression. One patient
experienced a transient respiratory degradation after treatment.
Discussion and conclusion.– Botulinum toxin therapy provided clinical
amelioration of spasticity in more than a half of our patients. One patient
had a transient respiratory degradation. To our knowledge, no study has been
reported about the efficacy and tolerance of toxin therapy in spasticity
management of LAS patients. This treatment is used to treat hypersialorrhea,
without severe side effect [2]. Nevertheless, the treatment should be started with
low doses. As LAS patients often suffer from severe motor loss, motor bloc of
the nerve of rectus femoris muscle should be perform before of botulinum toxin
injections in this muscle.
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Introduction.– Botulinum toxin is the first-line therapy in the management of
focal spasticity.
Through this work we want to evaluate our modest experience with the use of
this therapeutic method.
Materials and methods.– Fifty-two patients with focused spasticity due to
various pathologies were treated with botulinum toxin in the year 2011.
A pre therapeutic assessment and three weeks after injection of predetermined
muscles was performed taking into account the following parameters:
– the pain intensity assessed by visual analog scale;
– spasticity measured by Ashworth scale;
– the range of motion measured by goniometry;
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Results.– Among the 52 patients treated 64% were male, 37% are children aged
5 to 15 years. Hemiplegia and cerebral palsy represent 73% of diseases treated.
The equine foot was treated in 54% of cases where a percentage of 64% muscle
toxins represented by the triceps surae (42% of gastrocnemius, soleus 21%).
Before treatment, the mean VAS pain was 6.85, the average Ashworth was 3.1,
the mean range of motion (dorsiflexion of the ankle) was 78. After treatment,
the mean VAS pain increased to 4.02 that of Ashworth 2, and the mean joint
amplitudes increased to 1.58.
Discussion.– The results obtained after injection of botulinum toxin in these 52
patients were satisfactory standard analgesic, hypertonic and joint mobility, by a
regression of pain intensity estimated at three points on average, a regression
point of the spasticity and a gain of passive joint movement of 8.58 on average.
These results have led to an improvement in the lives of patients at the
functional level with an average of 53.63% EVA satisfaction.
Conclusion.– Focal spasticity is causing functional impairment of a major
source of pain and muscle-tendon and articular use of botulinum toxin has
dramatically improved the lives of these 52 patients, hence the interest to
generalize this method therapeutic.
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Aim.– To establish if patients reporting unusual fatigue present generalized
diffusion of BoNTA. Fatigue after BoNTA injection is frequently reported in
literature (up to 18% of injected patients).
Material and methods.– Retrospective, monocentric study. Generalized
diffusion has been searched with s ingle fiber EMG (or Neuromuscular Jitter)
on striated muscles away from BoNTA injected muscles. Neuromuscular jitter
(NMJ) is compared between 16 patients with unusual fatigue after BoNTA
injection, 17 asymptomatic patients treated with BoNTA (control group), 19
patients suffering botulism-like syndrome having muscular deficit distant from
BoNTA injection site and three patients suffering botulism food poisoning.
Indications were treatment of neurogenic detrusor overactivity or spasticity.
NMJ is the gold standard for evaluating neuromuscular junction dysfunction.
Mean jitter, percentage of pathological fibers and number of conduction blocks
are compared between groups.
Results.– Mean jitter, percentage of pathologic fibers and conduction blocks for
asymptomatic patients differs from those of patients presenting distant muscular
deficit (P = 0.0001) and patients suffering botulism (P = 0.017). Mean jitter and
number of conduction blocks differs between patients presenting unusual
fatigue and patients presenting distant muscular deficit (P = 0.0005). No
significant difference appears between asymptomatics and patients relating
unusual fatigue after BoNTA treatment.
Discussion.– This study doesn’t give rise to generalized BoNTA diffusion in
patients reporting unusual fatigue after BoNTA treatment although jitter clearly
differs between patients presenting distant muscle weakness and control group.
Generalized neuromuscular disorder doesn’t seem to explain those fatigue
events. Several hypotheses can account for it: not enough patients in the group
reporting unusual fatigue, fatigue could be due to autonomic nervous system
disorder that is not explored with this single fiber EMG, immune mechanism.
Fatigue could be reported to initial disease.
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Objective.– Over the past few years, several studies have shown that a
botulinum toxin (BTX-A) injection in the rectus femoris muscle (RF) could
enhance stroke patients’ walking capacity (Robertson et al., 2009). However,
the mechanisms behind these benefits are still unknown. The aim of this study
was to compare the analytical effect of BTX-A in the RF muscle (passive stretch
and voluntary strength assessed by an isokinetic dynamometer) and functional
repercussions on gait (assessed by three-dimensional motion analysis) in spastic
hemiparetic patients with stiff knee gait (SKG) caused by RF spasticity.
Methods.– Ten stroke patients with SKG caused by RF spasticity were included
and evaluated before and after a BTX-A injection in RF. Analytical evaluations
consisted of: (i) a clinical examination; (ii) an assessment using an isokinetic
dynamometer with surface electromyography (in order to quantify passive
stretch and knee flexor and extensor voluntary strength; (iii) a three-dimensional
motion analysis gait assessment (in order to quantify spatiotemporal and
kinematic gait parameters).
Results.– One month after BTX-A injection in RF, the following results were
found: (i) a decrease in knee extensor strength and an increase in knee flexor
strength; (ii) no change in the intensity of extensor activity during passive
stretch; (iii) an increase in the angle at which the stretch reflex occurred. 3D
analyses showed an increase in gait speed, which was related to an increase in
cadence and an increase in peak knee flexion during swing phase.
Discussion.– The improvement in knee flexion following BTX-A injection in
RF seems to be related to an increase in the angle at which the stretch reflex
occurs with no change in intensity of the contraction. This change in the
threshold of the sensitivity of neuromuscular spindles infers that BTX-A affects
the motoneuron g-neuromuscular spindle synapse (Trompetto et al., 2006).
http://dx.doi.org/10.1016/j.rehab.2012.07.828
CO20-007-e
Biomechanical, clinical and gait analysis’ effects of BoNTA
injection in the rectus femoris muscle of incomplete SCI
patients
B. Bernuz a,*, F. Genet b, P. Terrat b, D. Pradon b, F. Barbot b, D. Bensmail b,
B. Bussel b
a Hoˆpital Leon-Berard, avenue du Dr-Armanet, BP 10121, 83400 Hye`res,
France
b CHU Raymond-Poincare, France
*Corresponding author.
E-mail address: b.bernuz@leonberard.com.
Keywords: Botulinum toxin; Rectus femoris; Spasticity; Stretch reflex; Stiff-
knee gait; Torque
Background.– An understanding of the mechanical effects of botulinum toxin
types A (BoNTA) on spastic and voluntary muscle contraction may help predict
functional responders.
Objective.– To compare the effect of BoNTA on voluntary and stretch reflex-
related torque (and angle at peak torque) produced by activation of the rectus
femoris (RF) muscle.
Methods.– A prospective open pilot study. n = 15 incomplete SCI patients,
impaired by a specific RF spasticity (n = 20), with RF hyperactivity in mid-
swing and a stiff-knee-gait quantified by formal Gait Analysis (GA), were
assessed before and after BoNTA injection (Botox, 200 UI). Main outcome
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